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Trends in survival of chronic lymphocytic
leukemia patients in Germany and the USA
in the first decade of the twenty-first
century
Dianne Pulte1,2*, Felipe A. Castro1, Lina Jansen1, Sabine Luttmann3, Bernd Holleczek4, Alice Nennecke5,
Meike Ressing6, Alexander Katalinic7, Hermann Brenner1,8,9 and GEKID Cancer Survival Working Group

Abstract
Background: Recent population-based studies in the United States of America (USA) and other countries have
shown improvements in survival for patients with chronic lymphocytic leukemia (CLL) diagnosed in the early
twenty-first century. Here, we examine the survival for patients diagnosed with CLL in Germany in 1997–2011.
Methods: Data were extracted from 12 cancer registries in Germany and compared to the data from the USA.
Period analysis was used to estimate 5- and 10-year relative survival (RS).
Results: Five- and 10-year RS estimates in 2009–2011 of 80.2 and 59.5 %, respectively, in Germany and 82.4
and 64.7 %, respectively, in the USA were observed. Overall, 5-year RS increased significantly in Germany and
the difference compared to the survival in the USA which slightly decreased between 2003–2005 and 2009–
2011. However, age-specific analyses showed persistently higher survival for all ages except for 15–44 in the
USA. In general, survival decreased with age, but the age-related disparity was small for patients younger than
75. In both countries, 5-year RS was >80 % for patients less than 75 years of age but <70 % for those age 75+.
Conclusions: Overall, 5-year survival for patients with CLL is good, but 10-year survival is significantly lower,
and survival was much lower for those age 75+. Major differences in survival between countries were not
observed. Further research into ways to increase survival for older CLL patients are needed to reduce the
persistent large age-related survival disparity.

Background
Chronic lymphocytic leukemia (CLL) is a relatively common form of leukemia with a varied prognosis, with
some patients having the condition without significant
pathology and requiring no treatment for many years
while others rapidly require treatment [1]. A number of
clinical markers and patient characteristics are used to
determine when a patient would need treatment and
what type of treatment is offered [2].
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Survival for patients with CLL has been documented
to have improved on a population level between the
1980s and early twenty-first century in the United
States of America (USA) [3]. Several recent publications have examined survival for patients with CLL in
Europe [4–8], including an analysis of survival of patients with hematologic malignancies in Germany [7],
but data on recent changes in survival for patients with
CLL by detailed age groups and gender are lacking.
In 2008, a collaborative project between the German
Cancer Research Center (DKFZ) and population-based
cancer registries throughout Germany was formed in
order to provide comprehensive monitoring of cancer
survival throughout Germany [9, 10]. In this study, we
provide up-to-date and detailed (age and sex specific)
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relative survival estimates of German CLL patients based
on data from 12 population-based cancer registries, covering 28.05 million inhabitants. We compare the results
to data obtained from the Surveillance, Epidemiology,
and End Results (SEER) database in order to provide an
international comparison using a widely accepted database of known high quality [11].

Methods
Data sources

A detailed description of the cancer registries from
which data were obtained has been previously published
[9, 10]. Briefly, data extracted from 12 cancer registries
throughout Germany were included. The 12 cancer
registries together provide data from a base population
of 28.05 million people. Patients aged 15 or older diagnosed with a first malignant tumor in 1997–2011 with a
follow-up date through December 2011 were initially
identified. Patients with the ICD-10 code C91.1 (CLL)
were selected for analysis.
In order to compare population level survival for CLL
in Germany with survival in the USA, data from the
SEER13 database were analyzed [11]. The same inclusion
criteria as for patients from the German cancer registries
were applied for the same time period. The SEER13
database includes data from 13 regional cancer centers
in the USA, covering a total population of about 41.5
million people. Centers are chosen for inclusion based
on their high quality and epidemiologically interesting
population groups. The SEER population is considered
to be similar to the general US population with respect
to most sociodemographic characteristics, although it
may be more affluent than average and may have slightly
higher-than-average survival for some cancers [12].
Statistical methods

Five- and 10-year relative survival estimates for the time
period 2009–2011 were calculated using period analysis.
Period analysis provides the most up-to-date long-term
survival estimates and has been shown to closely predict
long-term survival of patients diagnosed in the period of
interest (here, 2009–2011) [13, 14]. Age-adjusted survival estimates were derived by computing weighted
sums of age-specific survival estimates, using weights
according to the International Cancer Survival Standard
[15] (15–44, 45–54, 55–64, 65–74, and 75+). Because
survival for patients with CLL may vary by age and gender, survival was examined by major age groups as above
and by gender as well.
In order to minimize the effect of possible differences
in the risk of non-CLL-related death on the comparisons, relative survival was calculated. Relative survival
was calculated as the ratio of actual survival to expected
survival. Expected survival was estimated according to
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the Ederer II method [16] using life tables stratified by
age, sex, and calendar year obtained from the Federal
Statistical Office for Germany and from life tables stratified by age, sex, race, and calendar year for the USA
available from the Center for Disease Control and Prevention (CDC) [17]. Differences in 5- and 10-year relative survival between patients in Germany and the USA
were tested for statistical significance, overall and by single age groups, using model-based period analysis [18].
In model-based analyses, numbers of deaths were modelled as a function of period of follow-up, age group, and
country by Poisson regression with the logarithm of the
person-months at risk as offset.
To assess recent trends in survival, 5-year agestandardized relative survival was additionally estimated for the time periods 2003–2005, 2006–2008,
and 2009–2011 using modelled period analysis, and
trends over time were tested for statistical significance
by modelled period analysis. All calculations were carried out using SAS software (version 9.2, SAS, Carey,
NC, USA), using macros developed for period and
modelled period analysis [18, 19]. Statistical significance was defined by p values of <0.05.

Results
Overall, 22,257 cases of CLL were identified in the
German registries and 24,771 cases in the SEER database
in 1997–2011 (Table 1). Median age at diagnosis was 69
in Germany and 71 in the USA for all patients. For
women, the median age at diagnosis was 71 and 73 in
Germany and the USA, respectively. For men, the median ages were 68 and 70, respectively, for Germany and
the USA (Table 1). The proportion of cases notified to
the registry by death certificate only (DCO) for Germany
was 15.6 % and for the USA was 1.4 %. These patients
were excluded from the analysis because their survival
time was unknown.
Overall, 5-year-age-adjusted survival for patients with
CLL in Germany was 77.8 % in 2003–2005 and 80.2 %
in 2009–2011 (p = 0.004) (Table 2). When analysis by
gender was performed, there was a small but statistically
significant increase in survival for both men and women
at +2.9 and +2.0 % units, respectively, (p = 0.04) with
persistent survival advantages for women throughout
the periods of investigation. Age-specific survival
showed higher 5-year relative survival estimates in
2009–2011 for younger patients, ranging from 93.4 %
for ages 15–44 to 65.1 % for age 75+. A pattern of
slightly increasing survival was observed for all age
groups except for 55–64, although the increase was statistically significant for patients age 75+ only, with survival estimates of 62.3 % in 2003–2005 and 65.1 % in
2009–2011 (p = 0.03).
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Table 1 Number of cases and characteristics in Germany and
the USA for the period 1997–2011
Country

Source population Total
in 2011 (million) cases

Median age
at diagnosis

Microscopically
confirmed (%)

22,257

69

87.7

12,854

68

88.1

9403

71

87.2

15–44

452

NA

89.1

45–54

1639

NA

89.9

55–64

4350

NA

90.2

65–74

7518

NA

88.0

75+

8298

NA

84.9

24,771

71

89.4

14,831

70

89.6

9940

73

89.1

15–44

511

NA

94.5

45–54

2275

NA

91.9

55–64

5105

NA

90.2

Germany
Total

28.05

Gender
Male
Female
Age groups

USA
Total

41.5

Gender
Male
Female
Age groups

65–74
75+

6636

NA

90.4

10,244

NA

87.5

NA not applicable

For patients in the USA, overall age-adjusted 5-year
survival estimates were 80.7 % in 2003–2005 and 82.4 %
in 2009–2011 (p = 0.1). Analysis by gender likewise
showed higher survival among women than among men,
with slight, statistically not significant increases in survival over time for both men and women (Table 2).
When age-specific analysis was performed, a strong, statistically significant increase in survival was observed for
ages 45–54, with an increase of 7.8 % units between
2003–2005 and 2009–2011 (p = 0.0004). In the other age
groups, much more subtle, statistically not significant increases were observed.
Direct comparison between survival in Germany and
the USA was made (Table 3). Five-year relative survival
estimates were similar for Germany and the USA in
2009–2011, both overall and by gender- and age-specific
analyses. However, a trend towards better survival was
observed for patients in the USA at all ages except for
age 15–44.
Because CLL is not curable but has a long disease
course with a high percentage of 5-year survivors, 10year survival was also calculated. Ten-year relative survival for the years 2009–2011 was 59.5 % for Germany

and 64.7 % for the USA (Table 3). Age-specific analysis
showed lower 10-year survival for Germany at all ages
except for age 15–44, with the largest differences being
observed for ages 45–54 and 55–64 (−10.2 and −6.9 %
units, respectively) (Table 3). Analysis by gender showed
a significantly lower survival for men in Germany at 57.4
versus 63.0 % in the USA (p = 0.0001) and a slightly
smaller, not statistically significant difference for women
with survival estimates of 63.6 and 67.9 %, respectively,
in Germany and the USA. When gender- and agespecific analyses were performed, survival was lower in
Germany for each age group and both genders with the
exception of men age 15–44. The largest differences
were for men at age 55–64 at −11.0 % units (p = 0.005)
and men and women age 45–54 at −10.6 % units for
both (p = 0.04 for men, p = 0.05 for women).
When survival by year after diagnosis was examined,
there was a nearly linear decrease from 1- to 10-year
relative survival in both Germany and the USA (Fig. 1).
It is notable that a plateau in survival was not observed
in either Germany or the USA in any age group or at
any time after diagnosis, demonstrating that long-term
survivors are not cured but continue to be at risk from
the disease. Survival decreased with age for patients diagnosed in Germany, but in the USA, survival was actually consistently better for patients age 45–54 than for
ages 15–44.

Discussion
Overall, 5-year relative survival has reached levels of
greater than 75 % or higher in CLL patients in Germany
and the USA. Survival estimates varied relatively little
between the two countries, although a statistically significant difference was observed for men and for all patients age 45–54 concerning 10-year relative survival.
Although survival decreases with age, the decrease is not
as abrupt as that seen in some other hematologic malignancies, with survival estimates for ages 45–54 being
fairly similar to those for ages 15–44. Five-year relative
survival increased only slightly in the calendar periods
examined. Ten-year survival was lower than 5-year survival, probably indicating ongoing mortality due to CLL,
although due to the nature of the analysis, 10-year survival estimates included older data than 5-year survival
estimates. Women had a higher survival estimate in both
countries, consistent with prior studies which have
shown longer survival and better response to therapy in
women [20].
CLL is a heterogeneous disease with variable presentation. Appropriate therapy can include observation,
chemotherapy, chemoimmunotherapy, or hematopoietic
stem cell transplant, depending on disease and patient
characteristics. Survival for patients with CLL has been
documented to have increased since the late twentieth
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Table 2 Trend analysis of 5-year-period relative survival for age-group-specific and age-adjusted CLL in Germany and the USA
Variable

2003–2005

2006–2008

2009–2011

p Value

Difference

0.8

0.004

+2.4

1.0

0.04

+2.9

82.9

1.1

0.04

+2.0

2.5

93.4

2.5

0.7

+2.5

1.6

91.5

1.6

0.1

+4.3

86.4

1.3

85.9

1.3

0.9

−0.6

80.4

1.3

81.7

1.2

0.06

+2.2

2.7

67.6

2.1

65.1

1.9

0.03

+2.9

80.7

0.8

83.8

0.7

82.4

0.7

0.1

+1.7

79.7

1.1

82.0

1.0

81.4

1.0

0.2

+1.7

82.6

1.2

86.4

1.0

84.2

1.0

0.4

+1.6

15–44

89.9

2.8

90.4

3.1

91.4

3.1

0.8

+1.5

45–54

87.3

1.7

94.0

1.3

95.1

1.2

0.0004

+7.8

55–64

87.6

1.3

89.1

1.2

88.7

1.1

0.5

+1.1

65–74

82.6

1.5

86.0

1.3

83.2

1.3

0.9

+0.6

75+

68.4

1.8

71.6

1.7

69.3

1.6

0.7

+0.9

Relative survival

SE

Relative survival

SE

Relative survival

SE

Alla

77.8

1.0

80.5

0.8

80.2

Malea

75.5

1.5

80.5

1.2

78.4

80.9

1.4

80.9

1.1

15–44

90.9

3.4

94.0

45–54

87.2

2.2

93.0

55–64

86.5

1.4

65–74

79.5

1.6

75+

62.3

Alla
Malea

Germany

a

Female

Age group

USA

a

Female

Age group

p value for trend, derived from the model. Diff = change from 2003–2005 to 2009–2011
SE standard error
a
Age adjusted

century in most population-based studies [3, 21, 22],
although others have found no major difference in survival during similar time periods [23]. Our current data
suggest that there continues to be incremental improvement in survival for patients with CLL, which was most
pronounced among patients age 45–54 in the period
studied. Interestingly, the increase in survival for patients age 45–54 between 2003–2005 and 2009–2011
made this population’s relative survival more similar to
that of the next younger age group.
Changes in survival in CLL may be due to better understanding of prognosis, leading to more appropriate
therapy, or changes in therapy. Classic prognostic factors
in CLL include clinical factors such as Rai stage, age,
gender, and comorbid conditions as well as laboratory
factors such as lymphocyte doubling time [24]. Additional major prognostic indicators include CD38 expression, presence or absence of mutation in the variable
heavy immunoglobin (IgVH), and specific cytogenetic
abnormalities [25]. Both CD38 expression and IgVH mutation status were reported as important clinical markers
in 1999 [26, 27]. ZAP70 expression has been used as an
easier-to-measure proxy for IgVH mutational status [28].
Specific chromosomal abnormalities associated with poor

outcomes have been reported since 2000 as well [29].
Other markers of poor prognosis have been proposed
[30–32], and thus further refinement of prognostic stratification may be expected to continue.
In terms of treatment, several changes have occurred
in the early twenty-first century. Starting in about the
year 2000, several clinical trials demonstrated better response and progression-free survival for high risk patients treated with fludarabine versus alkylating agents
[33, 34]. Although the monoclonal antibody rituximab is
not an effective therapy for CLL as monotherapy, its
introduction into combination chemotherapy regimens
along with fludarabine and possibly an alkylating agent
has led to improved survival for younger and fit patients
(though it may be too toxic for older or less fit patients)
[35]. Bendamustine is a highly active agent in CLL as
well, with response rates approaching 90 % in clinical
trials [36]. It has been used for longer in Germany than
in the USA but has become one frequently used option
in both countries. A trial directly comparing bendamustine and rituximab versus fludarabine, an alkylating
agent, and rituximab was recently completed [37], and
initial results suggest fludarabine, cyclophosphamide,
and rituximab (FCR) may be superior for fit patients
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Table 3 Five- and 10-year-period relative survival for patients with CLL in 2009–2011
5-year RS (SE)
Germany

5-year RS (SE) USA Difference p (country)

10-year RS (SE)
Germany

10-year RS (SE) USA Difference p (country)

80.2 (0.8)

82.4 (0.7)

−2.2

0.09

59.5 (1.3)

64.7 (1.1)

−5.2

0.0001

78.4 (1.0)

81.4 (1.0)

−3.0

0.07

57.4 (1.8)

63.0 (1.5)

−5.6

0.0001

82.9 (1.1)

84.2 (1.0)

−1.3

0.7

63.6 (1.8)

67.9 (1.6)

−4.3

0.1

15–44

93.4 (2.5)

91.4 (3.1)

+2.0

0.7

78.4 (4.4)

75.9 (4.6)

+2.5

0.7

45–54

91.5 (1.6)

95.1 (1.2)

−3.6

0.1

72.9 (2.7)

83.1 (2.1)

−10.2

0.007

55–64

85.9 (1.3)

88.7 (1.1)

−2.8

0.2

64.9 (1.9)

71.8 (1.8)

−6.9

0.009

65–74

81.7 (1.2)

83.2 (1.3)

−1.5

0.6

59.4 (1.9)

64.6 (1.9)

−5.2

0.08

75+

65.1 (1.9)

69.3 (1.6)

−4.2

0.8

42.6 (3.1)

49.0 (2.4)

−6.4

0.4

15–44

95.7 (2.5)

90.3 (4.3)

+2.4

0.3

78.2 (5.6)

72.0 (6.0)

+6.2

0.4

45–54

89.9 (2.1)

94.5 (1.7)

−4.6

0.09

68.8 (3.7)

79.4 (2.8)

−10.6

0.04

55–64

84.8 (1.7)

86.9 (1.5)

−2.1

0.4

59.1 (2.5)

70.1 (2.2)

−11.0

0.005

65–74

79.2 (1.6)

81.5 (1.7)

−2.3

0.5

56.7 (2.6)

61.7 (2.5)

−5.0

0.2

75+

62.1 (2.7)

69.2 (2.3)

−7.1

0.4

44.6 (4.9)

49.7 (3.5)

−5.1

0.3

15–44

88.0 (5.9)

92.3 (4.7)

−4.3

0.6

77.5 (7.5)

81.5 (7.1)

−4.0

0.6

45–54

94.9 (2.2)

96.2 (1.8)

−1.3

0.6

79.3 (4.0)

89.9 (2.9)

−10.6

0.05

55–64

87.9 (2.0)

91.7 (1.6)

−3.8

0.2

74.1 (2.8)

74.5 (2.9)

−0.4

0.6

65–74

85.8 (1.7)

86.1 (2.0)

−0.3

0.9

63.8 (2.9)

69.5 (2.9)

−5.7

0.3

75+

68.3 (2.6)

69.4 (2.3)

−1.1

0.6

42.8 (4.1)

48.6 (3.2)

−5.8

0.8

Alla
Gender
Malea
a

Female

Age group

Males

Females

RS relative survival, SE standard error, p (country) p value for comparison between the USA and Germany
a
Age adjusted

without p17-, but not in older patients or those with
more comorbidities. Other agents and combinations of
these agents with fludarabine, rituximab, or other agents
have increased the options for treating patients with
CLL as well [20]. Very recent clinical trials of newer
agents such as idelalisib and ibrutinib have shown dramatic improvements in survival in patients with CLL in
those trials [38, 39], but the results of these new treatment options will not be evident on the population level
for some time. However, data from clinical trials suggest
that these and similar agents may substantially alter the
natural history of the disease [40]. In addition, they are
well tolerated and can be given to patients with poor
performance status who make up a large proportion of
CLL patients. Thus, current survival expectations for patients with CLL may be underestimated by our study
due to changes in treatment that have occurred in the
last 3 years and are therefore not yet available in the
population level databases. Finally, stem cell transplant
is an option for fit patients with poor prognosis disease
and otherwise good clinical status [41]. Stem cell transplantation offers the only potential for cure in patients
with CLL but is used only in a minority of cases because

of the risk of early mortality and morbidity due to the
treatment and the relatively low risk nature of many
CLL clones.
Strengths of our study include the use of large databases with survival information from a number of regions in each country sampled, allowing for evaluation
of survival and subgroup analysis of this relatively rare
leukemia and decreasing the risk that survival differences between individual areas in each country will unduly influence the impression of survival in that country
overall. Use of population level data provides a more accurate understanding of how probable it is for a patient
with a given disease in the general population to survive
in contrast to data provided by clinical trials which tend
to present the best-case scenario with respect to survival
(i.e., only patients with good performance status and few
or no comorbidities are generally eligible for clinical trial
participation) and may not be realistic for the general
population [42]. Additionally, the use of period analysis
and modelled period analysis provides the most up-todate estimates of possible survival [14, 18].
In interpreting our results, several limitations should
also be considered. First, despite the large databases, the
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Fig. 1 Ten-year relative survival for patients with CLL in 2009–2011 in a Germany and b the USA by age group: overall (solid line), 15–44 (dashed
line), 45–54 (dotted line), 55–64 (dot/dash line), 65–74 (long dash line), and 75+ (long dash/dot line)

relative rarity of CLL limits our ability to detect minor
differences in survival, especially for younger patients in
whom the condition is rarer. Second, in the absence of a
national death index in Germany, most cancer registries
rely on record linkage with vital statistics from the state
that they cover and may miss deaths among patients
who move out of the state. Nevertheless, previous validation studies have suggested potential overestimation of
survival due to deaths missed by migration to be very
small [43]. In the USA, deaths are derived from the

National Death Index, and therefore this is less of a
problem, though the possibility of missing deaths because patients move out of the country is a potential
concern. Third, information on treatment, particularly
chemotherapy, and disease biology are very limited or
absent in both databases, and therefore we cannot definitely establish the extent to which treatment and differences in disease biology (i.e., frequency of heavy chain
rearrangement or chromosomal abnormalities) affect observed differences in survival or changes in survival over

Pulte et al. Journal of Hematology & Oncology (2016) 9:28

time. Fourth, there is some evidence that survival estimates from the SEER database may be higher than survival in the US population in general [11], so some
caution is necessary when comparing survival in the two
countries. Fifth, registry samples in Germany have changed over time, i.e., some registries started later, and
therefore the underlying population is not entirely consistent throughout the study period. Sixth, changes in
the diagnostic criteria of CLL made in 2008 requiring a
B-cell count of greater than 5000 [1] may have subtly
changed the population diagnosed, resulting in later
diagnosis of CLL and therefore a shorter “patient career”
for patients diagnosed after that time, potentially obscuring some increases in survival in the later time period.
However, any changes due to this issue would be present
in both countries.
Finally, several of the newer German registries are still
in the build-up phase and the proportion of cases identified by DCO is still relatively high in some of these
registries, especially at earlier time points. Exclusion of
these DCO cases in the analysis may have led to some
overestimation of survival in Germany. As a result, the
survival gap between the USA and Germany may have
been underestimated to some extent [43, 44].

Conclusions
In summary, high 5-year relative survival for patients
with CLL in Germany and the USA are meanwhile observed on the population level, exceeding 90 % in patients age 54 or younger and over 75 % overall. Ongoing
increases in survival were observed overall for Germany
and in the USA in the first decade of the twenty-first
century. Further research into ways to increase survival
for older CLL patients are needed to reduce the persistent large age-related survival disparity.
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